STOCKS TELEGRAPH

Tag: Windtree

  • Windtree Therapeutics (WINT) Climb Amid New Licensing Deal

    Windtree Therapeutics (WINT) Climb Amid New Licensing Deal

    Following the news of a license deal with Evofem Biosciences, Inc. (OTCQB: EVFM), shares of Windtree Therapeutics, Inc. (NASDAQ: WINT) saw a sharp increase. WINT stock was selling at $2.70 as of the most recent market check, representing a remarkable 59.48% rise.

    PHEXXI Strategic Licensing Agreement

    Windtree Therapeutics (WINT) has secured its position as the sourcing partner for Evofem’s FDA-approved contraceptive medicine, PHEXXI, by entering into a License and Supply Agreement.

    Lactic acid, citric acid, and potassium bitartrate are the ingredients in this prescription vaginal gel, which provides women with a hormone-free, controllable method of contraception on demand. With yearly sales of over $19 million and the sale of over 96,000 boxes of 12 pre-filled applicators in 2024, PHEXXI has seen significant market expansion.

    Lowering Manufacturing Costs for Global Expansion

    Windtree wants to drastically lower the cost of producing PHEXXI by utilizing its current manufacturing network. As per the deal, WINT will serve as Evofem’s sourcing partner, discussing cost-cutting measures with pharmaceutical producers. Notwithstanding this collaboration, Evofem will continue to hold PHEXXI and pursue strategic alliances to further commercialize the drug in both domestic and foreign markets.

    This partnership is in line with Windtree’s overarching business plan, which was revealed in January 2025 and calls for the company to become a profitable biotechnology company. With the deal with Evofem, the business takes the first step toward long-term success.

    Enhancing Market Accessibility

    In order to expedite the transfer of technology and supervise the manufacturing of first and validation batches in accordance with FDA rules, Windtree has already started talks with a pharmaceutical manufacturer. High production costs have been a significant obstacle for Evofem, impeding attempts at international commercialization.

    This collaboration with Windtree is anticipated to allow Evofem to launch PHEXXI into price-sensitive international markets, where there is still a high demand for non-hormonal contraceptive choices, by significantly reducing the product’s per-box cost.

    By taking this calculated step, both businesses want to increase access to PHEXXI and reaffirm their dedication to offering creative and reasonably priced healthcare options to women everywhere.

  • Windtree (WINT) Sees Pre-Market Surge Following Key Patent Milestone

    Windtree (WINT) Sees Pre-Market Surge Following Key Patent Milestone

    Today’s premarket trading is seeing a significant increase in Windtree Therapeutics, Inc. (NASDAQ: WINT) shares. As of the latest check, WINT stock was trading at $2.10 gaining a notable ration of 12.90%. The spike comes after a big change in the company’s portfolio of intellectual property.

    Patent Approval for a Novel Treatment

    The United States Patent and Trademark Office (USPTO) has granted a Notice of Allowance for U.S. application number 18/150,870, announced Windtree Therapeutics. The intravenous formulation of istaroxime used to treat acute heart failure (AHF) is the subject of this patent.

    Improvements in therapy are essential since AHF affects millions of people worldwide and strains healthcare systems financially. An important milestone in the company’s plan to enhance its portfolio of intellectual property (IP) in the US market is the approval.

    Istaroxime: An Innovative Two-Mechanism Treatment

    Istaroxime is a novel medication that works by improving both the diastolic and systolic functioning of the heart. Its efficacy has been shown by data from several Phase 2 clinical trials including individuals with acute decompensated heart failure or early cardiogenic shock.

    Istaroxime, when given intravenously, dramatically lowers blood pressure and improves cardiac function without increasing heart rate or disrupting cardiac rhythm. These encouraging outcomes support its potential as a game-changing therapy for those with heart failure.

    Internationalization of Intellectual Property Policy

    Windtree Therapeutics has also filed a national phase patent application with the Indian Patent Office, in keeping with its larger patent strategy. In this application, istaroxime and its derivatives are used to prevent or lower the risk of acute cardiac arrhythmia. It claims precedence over PCT/US2024/058923.

    For patients suffering from heart failure and cardiomyopathy, arrhythmias—which are typified by irregular heartbeats—present a serious risk. The effectiveness of the heart’s blood pumping capacity may be diminished by several disorders. Particularly, cardiac arrhythmias have the potential to be fatal.

    A critical strategy as Windtree Therapeutics (WINT) moves closer to Phase 3 readiness in the treatment of cardiogenic shock is to get patent protection in India, a country with a population of over 1.4 billion.

  • Windtree (WINT) Stock Climbs In Pre-Market Trading After Major Update

    Windtree (WINT) Stock Climbs In Pre-Market Trading After Major Update

    The disclosure of progress in a clinical study has resulted in a large boost in the stock value of Windtree Therapeutics, Inc. (NASDAQ: WINT). As of the latest pre-hours check, Windtree stock has risen 55.12% to $4.95.

    Windtree Completed Enrollment In A Significant Study

    The SEISMiC Extension Phase 2b trial, conducted by Windtree Therapeutics to examine the effectiveness of istaroxime in treating early cardiogenic shock occurring from heart failure, has successfully concluded patient enrollment. The purpose of this study is to evaluate istaroxime’s ability to improve heart function and maintain hypotension in early cardiogenic shock cases.

    WINT is Building on Previous Positive Results

    The current SEISMiC Extension Study seeks to extend the promising outcomes observed in the earlier SEISMiC Phase 2 study. This prior research suggested that istaroxime could positively impact renal function and did not contribute to an increase in cardiac arrhythmias.

    The Extension Study employs a prolonged dosing regimen with gradual tapering to evaluate the potential benefits further. Istaroxime, a pioneering first-in-class therapy, has previously shown its ability to improve systolic contraction, diastolic relaxation, and blood pressure, while also supporting or enhancing renal function in patients with acute heart failure through three successful Phase 2 trials.

    International Scope and Future Prospects

    Conducted across the U.S., Europe, and Latin America, the SEISMiC Extension Study aims to build upon the favorable results of the initial SEISMiC Phase 2 study. The study focuses on optimizing dosages and further exploring istaroxime’s novel SERCA2a mechanism, which could offer significant advantages for patients experiencing cardiogenic shock.

    Additionally, detailed data on cardiac function and safety, particularly regarding arrhythmias, are being collected. Windtree Therapeutics believes that istaroxime’s lack of association with increased cardiac arrhythmias could differentiate it from existing therapies.

    Next Steps and Anticipated Results

    Completing enrollment in the SEISMiC Extension Study represents a critical milestone for advancing the istaroxime program towards Phase 3 trials. Concurrently, the SEISMiC C study continues to explore more severe cardiogenic shock cases. Windtree anticipates releasing topline results from the SEISMiC Extension Study by the end of the month and plans to present these findings at an upcoming major medical conference.

  • Windtree (WINT) Sees Major Market Gains After Istaroxime Trial Progress

    Windtree (WINT) Sees Major Market Gains After Istaroxime Trial Progress

    Windtree Therapeutics, Inc. (NASDAQ: WINT) has experienced a significant rise in the value of its shares following the most recent report on its clinical studies. The latest current-market check showed that WINT shares have increased by 104.55% to $6.75.

    Windtree Advancing The Clinical and Business Development of Istaroxime

    Significant advancements have been made in the clinical and corporate development domains for Windtree Therapeutics’ primary treatment, istaroxime. This novel, first-of-its-kind treatment aims to raise blood pressure, maintain or improve renal function, and improve the heart’s systolic and diastolic contraction and relaxation. Three Phase 2 trials involving patients with acute heart failure (AHF) and early cardiogenic shock have shown encouraging results with isostaroxime.

    SEISMiC Extension Study and Future Prospects

    In alignment with prior projections, Windtree expects to complete enrollment for its Phase 2 SEISMiC Extension Study in patients with early cardiogenic shock (SCAI Stage B) within the next several weeks. The company anticipates reporting topline data by the end of this quarter. Building on the favorable results of the initial SEISMiC study, the Extension Study aims to optimize dosing and further characterize the effects of SERCA2a for planning Phase 3 trials, targeting an enrollment of up to 30 patients.

    This study assesses the impact of two dosing regimens of istaroxime compared to a placebo in hospitalized patients with early cardiogenic shock due to AHF. Patients will receive istaroxime infusions for up to 60 hours, with one group experiencing a decreasing dose over time and the other group receiving a consistent dose. This extended dosing period is a step up from the previous SEISMiC study, which had a 24-hour treatment duration.

    Potential and Differentiation of Istaroxime

    Windtree posits that extending the duration of istaroxime dosing could offer additional benefits, and dose titration is crucial for determining the optimal regimen for late-stage trials. The Extension Study is also collecting detailed data on heart function, particularly related to the SERCA2a mechanism of action. Notably, istaroxime has not been linked to an increase in cardiac arrhythmias, setting it apart from currently used inotropes and vasopressors.

    The Extension Study continues to measure the effects of istaroxime on blood pressure and cardiac function, with results anticipated to mirror the improvements seen in the original SEISMiC study. In parallel, Windtree is preparing to initiate a study in patients with more severe cardiogenic shock (SCAI Stage C), representing a more critically ill population than those previously studied.

  • Windtree Therapeutics, Inc. (WINT) Stock Exhibits Minor Volatility Despite Promising Istaroxime Developments

    Windtree Therapeutics, Inc. (WINT) Stock Exhibits Minor Volatility Despite Promising Istaroxime Developments

    Windtree Therapeutics, Inc. (WINT) stock prices were down by 6.56% as of the market closing on July 16th2021, bringing the price per share down to USD$1.71 at the end of the trading day. Premarket fluctuations saw the stock rise by 6.43%, bringing it up to USD$1.82.

    Istaroxime Study

    May 2021 saw the company reiterate the expansion of the counties and sites participating in its Phase 2 global clinical study. The study is for istaroxime, which is being evaluated as a viable treatment option for Early Cardiogenic Shock in patients having suffered from severe acute heart failure. A severe form of heart failure, cardiogenic shock is marked by critically low blood pressure. The development of the treatment is founded in observations from the acute heart failure program and will serve to assess istaroxime’s ability to improve blood pressure. The study is expected to be completed by the second half of 2021.

    Istaroxime Patent Protection

    The company has also been seeking additional expedited patent protection for istaroxime, their lead asset. To facilitate this, WINT filed a Track One prioritized patent application with the U.S Patent and Trademark Office, with the associated patent being derived from an application previously filed under the Patent Cooperation Treaty. As per the Track One program, the new patent for istaroxime is forecasted to receive a review and final disposition according to an accelerated timeline. The priority status being granted, the company expects finalizations within a year, as compared to the typical three-year examination for non-prioritized examinations.

    Solid Liquidity Position

    The first quarter of 2021 saw WINT complete an equity financing program, which saw the company generate almost USD$30 million in gross proceeds, before the deduction of expenses related to the offering. Net proceeds from the offering came out to roughly USD$27.4 million, contributing to the company’s solid liquidity position as of March 31st, 2021, when WINT announced having cash and cash equivalents in the amount of USD$38.5 million.

    Net Loss Reports

    WINT reported a net loss of USD$9 million on 17.7 million weighted-average common shares outstanding as of the end of the first quarter of 2021, representing a net loss of USD$0.57 per basic share. The is comparable to the UD$6.5 million net loss reported for the prior-year period, which had 13.7 million weighted average common shares outstanding, representing a net loss of USD$0.48 per basic share.

    Future Outlook for WINT

    Armed with a comfortable liquidity position and strategic partnerships that aim to develop treatments through to commercialization and proliferation, WINT is poised to capitalize on the opportunities afforded to it. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.